公开(公告)号：US20210346436A1

公开(公告)日：2021-11-11

申请号：US17379671

申请日：2021-07-19

Applicant: METCELA INC.

Inventor： Takahiro IWAMIYA

IPC: A61K35/33 ,  A61P9/04 ,  A61P9/10 ,  A61K9/00

Abstract: The present invention aims to provide a method which has not been established yet and which is useful for achieving long-term and fundamental cure of a necrotic cardiac tissue region to allow recovery of functionality of the heart.
The present invention provides an injectable composition for treatment of a cardiac disease, the composition comprising fibroblasts, wherein the fibroblasts contain CD106-positive fibroblasts, preferably contain CD90-positive fibroblasts, and the fibroblasts do not form colonies.

公开(公告)号：US20240148795A1

公开(公告)日：2024-05-09

申请号：US18548803

申请日：2022-03-03

Applicant: METCELA INC.

Inventor： Takahiro IWAMIYA

IPC: A61K35/33 ,  A61P11/00 ,  A61P43/00

CPC classification number: A61K35/33 ,  A61P11/00 ,  A61P43/00

Abstract: A fibroblast highly expressing ADM and/or HHEX has been found as a cell having lymphangiogenesis ability, and a procedure for treating fibrosis, a procedure for ameliorating a condition of lymphangiogenesis ability reduced, and procedures for modulating homeostasis of a tissue fluid, transport of lipid and/or vitamin, and immunological surveillance, and for treating organ failure, by use of a pharmaceutical composition including the fibroblast, have been found. In addition, it has been found that an adult-derived fibroblast highly expressing ADM and increasing expression of VCAM-1 is obtained by culturing a human fibroblast with a medium to which TNF-α and IL-4 are added and it has been found that a fibroblast highly expressing ADM is provided, and a procedure for treating a pulmonary disease by use of the fibroblast has been found.

公开(公告)号：US20180369288A1

公开(公告)日：2018-12-27

申请号：US16106723

申请日：2018-08-21

Applicant: METCELA INC.

Inventor： Takahiro IWAMIYA ,  Katsuhisa MATSUURA

IPC: A61K35/33 ,  C12N5/077 ,  C12N1/00

Abstract: The purpose of the present invention is to provide a cardiac cell culture material which specifically acts on cardiac cells. In addition, another purpose of the present invention is to provide artificial organ material obtained by culturing by using said cardiac cell culture material, and a method for producing the same. Thus, provided is a cardiac cell culture, wherein functional cardiac tissue is favorably built by using a cardiac cell culture material containing VCAM-1.

公开(公告)号：US20220411761A1

公开(公告)日：2022-12-29

申请号：US17929052

申请日：2022-09-01

Applicant: Metcela Inc.

Inventor： Takahiro IWAMIYA

IPC: C12N5/071 ,  A61P13/12

Abstract: It was found that, by culturing human fibroblasts using a medium supplemented with TNF-α and IL-4, EPO productivity in the fibroblasts can be improved. As a result, fibroblasts having enhanced EPO productivity were found, and means for improving a state where EPO productivity is decreased, and means for treating renal disorder or renal anemia, using the cells were discovered.

公开(公告)号：US20190224250A1

公开(公告)日：2019-07-25

申请号：US16263321

申请日：2019-01-31

Applicant: METCELA INC.

Inventor： Takahiro IWAMIYA

IPC: A61K35/33 ,  A61K9/00 ,  A61P9/10 ,  A61P9/04

Abstract: The present invention aims to provide a method which has not been established yet and which is useful for achieving long-term and fundamental cure of a necrotic cardiac tissue region to allow recovery of functionality of the heart.The present invention provides an injectable composition for treatment of a cardiac disease, the composition comprising fibroblasts, wherein the fibroblasts contain CD106-positive fibroblasts, preferably contain CD90-positive fibroblasts, and the fibroblasts do not form colonies.

公开(公告)号：US20210254009A1

公开(公告)日：2021-08-19

申请号：US17187459

申请日：2021-02-26

Applicant: METCELA INC.

Inventor： Takahiro IWAMIYA ,  Tomoyuki OSUGI ,  Masaya SUZUKI

IPC: C12N5/077 ,  A61L27/38 ,  A61P9/00

Abstract: It was found that culturing of fibroblasts in the presence of effective amounts of Tumor Necrosis Factor-alpha (TNF-α) known as a factor that induces hemorrhagic necrosis of tumor and Interleukin-4 (IL-4) known for its role in onset of allergic reactions leads to increase in the number of CD106-positive and G-CSF-positive fibroblasts.

公开(公告)号：US20170112880A1

公开(公告)日：2017-04-27

申请号：US15401832

申请日：2017-01-09

Applicant: METCELA INC.

Inventor： Takahiro IWAMIYA ,  Katsuhisa MATSUURA

IPC: A61K35/33 ,  A61K38/17 ,  C12N5/077

CPC classification number: A61K35/33 ,  A61F2/24 ,  A61K38/1774 ,  C12N1/00 ,  C12N5/0656 ,  C12N5/0657 ,  C12N5/10 ,  C12N2501/58 ,  C12N2502/1329

Abstract: The purpose of the present invention is to provide a cardiac cell culture material which specifically acts on cardiac cells. In addition, another purpose of the present invention is to provide artificial organ material obtained by culturing by using said cardiac cell culture material, and a method for producing the same. Thus, provided is a cardiac cell culture, wherein functional cardiac tissue is favorably built by using a cardiac cell culture material containing VCAM-1.